Vaccines
•47 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (47)
| Company | Market Cap | Price |
|---|---|---|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$268.36B |
$109.05
+1.49%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$143.11B |
$25.51
+1.35%
|
|
CVS
CVS Health Corporation
CVS administers vaccines across its pharmacy network, a direct service offering.
|
$102.00B |
$80.81
+0.48%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$57.33B |
$129.53
+0.12%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda markets vaccines (QDENGA) and maintains a vaccines-focused portfolio.
|
$49.74B |
$15.80
+0.73%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$23.22B |
$98.44
+1.64%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$12.52B |
$35.54
+10.48%
|
|
RDY
Dr. Reddy's Laboratories Limited
Strategic emphasis on vaccines, including RSV vaccine programs.
|
$11.53B |
$13.87
+0.36%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.45B |
$23.62
+2.49%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$5.98B |
$44.79
-2.69%
|
|
IBRX
ImmunityBio, Inc.
Vaccine vectors and vaccines pipeline (hAd5 vectors targeting TAAs).
|
$1.97B |
$2.13
+2.40%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.81B |
$15.44
+0.16%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.56B |
$39.56
+3.11%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.18B |
$7.41
+2.14%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor is developing a vaccine candidate via its StealthX platform in collaboration with Project NextGen.
|
$1.13B |
$26.19
+5.56%
|
|
CVAC
CureVac N.V.
The company is actively developing infectious disease vaccines using its mRNA backbone (Vaccines).
|
$1.05B |
$4.66
|
|
OPK
OPKO Health, Inc.
OPKO is advancing vaccines via EBV vaccine collaboration, a core vaccine development activity.
|
$1.02B |
$1.31
+2.73%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$685.56M |
$13.05
+1.56%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$614.69M |
$8.88
+0.28%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is a WT1-targeted cancer vaccine, fitting the Vaccines category as a therapeutic vaccine approach.
|
$526.49M |
$4.09
-18.10%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax-L and DCVax-Direct are therapeutic vaccines for cancer, aligning with Vaccines.
|
$474.35M |
$0.25
|
|
OCGN
Ocugen, Inc.
OCU500 represents an inhaled mucosal vaccine platform with a COVID-19 vaccine IND.
|
$423.84M |
$1.56
+7.93%
|
|
AHG
Akso Health Group
Vaccine research centers planned (AIDS and Covid-19) within the strategy.
|
$357.10M |
$1.56
+4.70%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$169.72M |
$6.21
+1.22%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-801 is a live virus vaccine candidate for mpox/smallpox, placing Tonix in vaccines development with potential commercialization.
|
$133.42M |
$15.16
-0.39%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$128.42M |
$8.03
+2.16%
|
|
FBIO
Fortress Biotech, Inc.
Fortress’ portfolio includes vaccine programs (Helocyte's Triplex CMV vaccine), aligning with Vaccines.
|
$127.05M |
$4.09
-4.10%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oravax Medical Inc., in which Oramed holds a majority stake, focuses on oral vaccines, making Vaccines a direct product category for the company.
|
$121.37M |
$3.03
+2.36%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
ANIX
Anixa Biosciences, Inc.
Breast and ovarian cancer vaccines constitute a direct vaccine product line.
|
$102.43M |
$3.22
+1.26%
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$86.89M |
$0.36
|
|
INO
Inovio Pharmaceuticals, Inc.
Pipeline includes Ebola vaccine booster (INO-4201) and other vaccine approaches; company develops vaccines using DNA plasmids.
|
$84.50M |
$1.57
-0.94%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Vaccines program (universal dengue vaccine) as an internal asset and potential product.
|
$74.24M |
N/A
|
|
TVGN
Tevogen Bio Holdings Inc.
TVGN 489 and the TVGN vaccine program indicate vaccine development capabilities (T cell vaccine approach).
|
$70.62M |
$0.34
-4.29%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$40.19M |
$0.64
+4.84%
|
|
PDSB
PDS Biotechnology Corporation
PDS0101/Versamune HPV functions as a therapeutic cancer vaccine, aligning with the Vaccines category.
|
$39.79M |
$0.91
+6.74%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Strategic collaboration on thermostable vaccines indicates vaccine development activity.
|
$34.98M |
$1.64
+2.50%
|
|
DYAI
Dyadic International, Inc.
Company has vaccine-related programs and antigen work (e.g., mpox ferritin nanoparticle vaccine antigen) via its platforms, aligning with vaccines.
|
$32.93M |
$0.92
+1.09%
|
|
BRNS
Barinthus Biotherapeutics plc
Pipeline includes vaccines (VTP-500 MERS) and vaccine-focused platforms.
|
$29.61M |
$0.70
-3.59%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN311 and PMN400 indicate a vaccine development program targeting amyloid and alpha-synuclein epitopes.
|
$18.63M |
$8.62
-1.54%
|
|
BCTX
BriaCell Therapeutics Corp.
Bria-IMT Bria-OTS involve cellular vaccine approaches in cancer, aligning with Vaccines.
|
$14.41M |
$7.17
-6.21%
|
|
IMNN
Imunon, Inc.
PlaCCine platform includes DNA-based vaccines (e.g., COVID-19 candidate), aligning with Vaccines.
|
$9.10M |
$4.16
+0.73%
|
|
ALZN
Alzamend Neuro, Inc.
ALZN002 is described as a vaccine-based active immunotherapy approach for Alzheimer's.
|
$6.44M |
$2.10
+2.20%
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$6.13M |
$1.43
-0.35%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$5.19M |
$4.92
+2.60%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$4.82M |
$0.22
+14.42%
|
|
IMRN
Immuron Limited
Travelan IMM-124E prophylactic product aligns with vaccines/immune prophylaxis category.
|
$4.67M |
$0.82
+0.01%
|
Loading company comparison...
Loading industry trends...
Loading research report...
